Itra VX 200 Capsule contains Itraconazole 200 mg, a broad-spectrum triazole antifungal agent used for the treatment of various fungal infections. Itraconazole exerts its antifungal activity by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a key component of fungal cell membranes. This disruption leads to increased membrane permeability and ultimately fungal cell death. Itra VX 200 is indicated for the management of systemic and superficial mycoses, including blastomycosis, histoplasmosis, aspergillosis, onychomycosis, and candidiasis. The capsule formulation ensures optimal bioavailability when taken with food, enhancing absorption. Dosage and duration of therapy depend on the type and severity of the infection, and treatment should be guided by clinical response and laboratory findings. Itra VX 200 should be used cautiously in patients with hepatic impairment or congestive heart failure, and potential drug interactions must be considered due to its effect on cytochrome P450 enzymes. Common adverse effects include gastrointestinal disturbances, headache, and rash. Regular monitoring of liver function tests is recommended during prolonged therapy. Itra VX 200 Capsule provides an effective antifungal option for clinicians managing complex fungal infections.